Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > This JUNK is FINISHED.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(45)
•••
Comment by SeeDonRunon Oct 09, 2021 6:52pm
177 Views
Post# 33992443

RE:This JUNK is FINISHED.

RE:This JUNK is FINISHED.

Sanotize is a preventative tool against COVID and has never been deemed anything more than that whereas R-107 is a treatment and possible cure for severe COVID infection, ARDs, PAH and Sepsis.  Until Sanotize lcenses R-107 from us to apply and enhance the effectiveness of their nasal sprays they have no effect on us whatsoever.

As for the pandemic being over, I doubt you can find any scientists out there who will show data that supports your contention that it is on it's way out the door.  In fact, pretty much all agree that we will be living wiith it for many years to come.

You on the other hand I suspect will not be with us much longer.  I should like to say that I wish you all the best and thanks for the entertainment.   

 

GreatGabbo wrote: SaNOtize is way too far ahead of this pig to ever see a bounce back. Pandemic is on its way out the door and soon people won't care for buzzwords. This is going to 5 cents.

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities